Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 6/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KCNJ2 | P63252 | 1/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL19097309 | 0.94 | KCNK3 (0.44) | KCNK3LMNATP53MAPTKCNJ2 | |
| SCHEMBL19123655 | 0.82 | GRIA2 (0.54) | KCNK3GRIA2CYP1A2CYP2C9 | |
| SCHEMBL17317595 | 0.81 | KCNK3 (0.52) | KCNK3GRIA2CYP2C9LMNATP53 | |
| SCHEMBL17317858 | 0.79 | KCNK3 (0.50) | KCNK3GRIA2CYP2C9LMNATP53 | |
| SCHEMBL17317859 | 0.77 | KCNK3 (0.44) | KCNK3GRIA2CYP2C9LMNATP53 | |
| SCHEMBL17317679 | 0.76 | KCNK3 (0.49) | KCNK3 | |
| SCHEMBL17317779 | 0.75 | KCNK3 (0.47) | KCNK3GRIA2CYP1A2CYP2C9LMNA | |
| SCHEMBL17328165 | 0.75 | ENPP2 (0.47) | KCNK3LMNATSHRNPSR1 | |
| SCHEMBL17328080 | 0.75 | ENPP2 (0.47) | KCNK3LMNATSHRNPSR1 | |
| SCHEMBL19097241 | 0.75 | ENPP2 (0.47) | KCNK3LMNATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | KCNK3 1825/4885GRIA2 794/4885CYP1A2 4507/4885 |
| US-10144732-B2 | ATX modulating agents | ENPP2, ATXN10, ATXN2 | KCNK3 1825/4885GRIA2 791/4885CYP1A2 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.